BIODANE PHARMA A/S: Financial statements 2017
CVR: 28310102
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
BIODANE PHARMA A/S (CVR 28310102) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 967,640 and a net result of DKK 102,788 compared with DKK 32,975 the year before. That is an increase of 29.5% compared with the year before. Equity in the 2017 report amounted to DKK 1,869,305. The solvency ratio was 90.5%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 967,640
- Profit/Loss
- DKK 102,788
- Equity
- DKK 1,869,305
- Total Assets
- DKK 2,065,279
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 968 t. | 103 t. | 1.9 mio. | 1 |
| 2016 | - | 747 t. | 33 t. | 767 t. | 1 |
| 2015 | - | 438 t. | -253 t. | 734 t. | - |
| 2014 | - | 279 t. | -250 t. | 987 t. | - |
| 2013 | - | 106 t. | -977 t. | -263 t. | - |
Official annual report
Keep an eye on BIODANE PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
BIODANE PHARMA A/S has published its annual report for 2016. Gross profit came to DKK 747,313, and the net result was DKK 32,975.
About BIODANE PHARMA A/S
BIODANE PHARMA A/S is a Danish company of the type Aktieselskab based in Gesten, founded in 2004. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named BIODANE PHARMA ApS and BIOFIBER TØRRING ApS. The management consists of Gunner Kreutzer Jakobsen. The board consists of Peter Gæmelke (chair), Flemming Torben Heden Knudsen, Gunner Kreutzer Jakobsen and Rasmus Juhl Rasmussen. The company is owned by BIODAN A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 2,534,166 and a net result of DKK 182,862 compared with DKK 1,651,356 the year before. Equity in the 2025 report amounted to DKK 2,505,002.